Gemzar

Gemzar is a medicine prescribed for the treatment of different types of cancer, such as ovarian cancer, breast cancer, and pancreatic cancer. Because the medication is administered intravenously (through an IV), it is usually given at a healthcare provider's office, a hospital, or an "infusion center." Commonly reported side effects of Gemzar include anemia, nausea, and vomiting.

What Is Gemzar?

Gemzar® (gemcitabine) is a prescription medication used to treat various types of cancer. Specifically, the medication is approved to treat:
 
(Click Gemzar Uses for more information on what the drug is used for, including possible off-label uses.)
 

Who Makes It?

Gemzar is currently made by Eli Lilly.
 

How Does Gemzar Work?

Gemzar is part of a group of medications called antimetabolites. Antimetabolites are medications that are similar to naturally occurring chemicals in the body that cells use to build DNA and other important parts of the cell. Antimetabolites are similar enough to these chemicals that cells mistake them for the real chemicals, using them to build DNA. However, antimetabolites are different enough that the DNA (or other cell structures) built using them will not function properly. Since DNA is essential for cells to grow and multiply, antimetabolite medications prevent cell growth and multiplication, and may cause cell death.
 
While Gemzar can kill both healthy and cancerous cells, it has a greater effect on cells that are multiplying rapidly. Generally, cancer cells multiply more rapidly than healthy cells and are, therefore, more affected by Gemzar.
 
Do You Recognize These 13 Celebrity E-Cigarette Smokers?

Gemzar Chemotherapy

Referring Pages:
Terms of Use
Advertise with Us
Contact Us
About eMedTV
Privacy Policy
Copyright © 2006-2017 Clinaero, Inc.
eMedTV serves only as an informational resource. This site does not dispense medical advice or advice of any kind. Site users seeking medical advice about their specific situation should consult with their own physician. Click Terms of Use for more information.